Literature DB >> 8902571

Treatment of the clinically negative neck in laryngeal cancer patients.

O Gallo1, V Boddi, G V Bottai, F Parrella, O F Storchi.   

Abstract

BACKGROUND: Elective treatment of the NO neck in patients with laryngeal cancer remains a controversial issue. We reviewed our experience with patients who had neck dissection for NO laryngeal carcinoma with occult metastases in order to compare elective lymphadenectomy results with those achieved with therapeutic neck dissection performed subsequently when occult disease became clinically evident.
METHODS: We retrospectively analyzed 150 NO laryngeal cancer patients who after a neck dissection had histologically positive lymph nodes and 5-year minimum follow-up. This population was divided in two subsets, including: 54 NO patients with occult neck metastases who had an elective neck surgery (ED); 96 initially NO patients who had a subsequent therapeutic neck dissection when nodal involvement became clinically detectable (STD). The two groups were compared with respect to the pattern of nodal metastasis and sites of treatment failures and also in terms of absolute, determinate, and actuarial survival.
RESULTS: Overall absolute survival was 72.2% in the elective dissected (ED) group, compared with 54.1% in the group of subsequent therapeutic dissected (STD) patients (p = 0.075). Determinate survival was 74.0% after ED and 59.3% after STD (p = 0.17). Actuarial curves by the Kaplan-Meier method did not show any statistically significant differences among the two groups analyzed (logrank test, p = 0.54). Accordingly, Cox multivariate analysis confirmed that neck treatment policy had no prognostic impact on survival in our NO laryngeal cancer patients. However, a higher proportion of STD patients died of metastases at distant sites compared with ED patients (21.9% vs 7.4%, respectively) (p = 0.02).
CONCLUSIONS: Elective lymphadenectomy does not significantly improve survival in NO laryngeal cancer patients with occult disease compared with those undergoing a therapeutic neck dissection when metastases subsequently appear.

Entities:  

Mesh:

Year:  1996        PMID: 8902571     DOI: 10.1002/(SICI)1097-0347(199611/12)18:6<566::AID-HED12>3.0.CO;2-6

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial.

Authors:  Francisco J Civantos; Robert P Zitsch; David E Schuller; Amit Agrawal; Russell B Smith; Richard Nason; Guy Petruzelli; Christine G Gourin; Richard J Wong; Robert L Ferris; Adel El Naggar; John A Ridge; Randal C Paniello; Kouros Owzar; Linda McCall; Douglas B Chepeha; Wendell G Yarbrough; Jeffrey N Myers
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

2.  Cytokeratin immunohistochemically detected nodal micrometastases in N0 laryngeal cancer: impact on the overall occult metastases.

Authors:  Hesham Negm; Mohamed Mosleh; Hesham Fathy; Amal Hareedy; Ahmad Elbattawy
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-05       Impact factor: 2.503

3.  Occult metastases from T1-T2 supraglottic carcinoma: role of primary tumor localization.

Authors:  Imdat Yüce; Sedat Cağli; Ali Bayram; Ercihan Güney
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-05       Impact factor: 2.503

4.  "Conditional" neck dissection in management of laryngeal carcinoma.

Authors:  R Fiorella; V Di Nicola; M L Fiorella; C Russo
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

5.  Evolution of elective neck dissection in N0 laryngeal cancer.

Authors:  O Gallo; A Deganello; J Scala; E De Campora
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

6.  Effectiveness and pitfalls of elective neck dissection in N0 laryngeal cancer.

Authors:  A Deganello; G Gitti; G Meccariello; G Parrinello; G Mannelli; O Gallo
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-08       Impact factor: 2.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.